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Background: The upper gastrointestinal tract is home to some of most notorious cancers like esophagogastric and
pancreatic cancer. Several factors contribute to the lethality of these tumors, but one that stands out for both
tumor types is the strong inter- as well as intratumor heterogeneity. Unfortunately, genetic tumor models do not
match this heterogeneity, and for esophageal cancer no adequate genetic models exist. To allow for an improved
understanding of these diseases, tissue banks with sufficient amount of samples to cover the extent of diversity of
human cancers are required. Additionally, xenograft models that faithfully mimic and span the breadth of human
disease are essential to perform meaningful functional experiments.
Methods: We describe here the establishment of a tissue biobank, patient derived xenografts (PDXs) and cell line
models of esophagogastric and pancreatic cancer patients. Biopsy material was grafted into immunocompromised
mice and PDXs were used to establish primary cell cultures to perform functional studies. Expression of Hedgehog
ligands in patient tumor and matching PDX was assessed by immunohistochemical staining, and quantitative
real-time PCR as well as flow cytometry was used for cultured cells. Cocultures with Hedgehog reporter cells were
performed to study paracrine signaling potency. Furthermore, SHH expression was modulated in primary cultures
using lentiviral mediated knockdown.
Results: We have established a panel of 29 PDXs from esophagogastric and pancreatic cancers, and demonstrate
that these PDXs mirror several of the (immuno)histological and biochemical characteristics of the original tumors.
Derived cell lines can be genetically manipulated and used to further study tumor biology and signaling capacity.
In addition, we demonstrate an active (paracrine) Hedgehog signaling mode by both tumor types, the magnitude
of which has not been compared directly in previous studies.
Conclusions: Our established PDXs and their matching primary cell lines retain important characteristics seen in
the original tumors, and this should enable future studies to address the responses of these tumors to different
treatment modalities, but also help in gaining mechanistic insight in how some tumors respond to certain
regimens and others do not.
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Despite the progress in both scientific understanding
and treatment of most tumor types, some malignancies
have remained notoriously difficult to treat. Good exam-
ples of such difficult cancers are those of the upper
gastrointestinal (GI) tract, including esophagogastric and
pancreatic adenocarcinoma. The incidences of these tu-
mors are increasing in the Western world and given that
their survival rates are not significantly improving, they
are within the leading causes of death by 2030 [1]. A
need to better understand these malignancies and to
develop models that address the crucial features that
render them so lethal is therefore apparent.
Contributing to the lethality of these cancers is the
large degree of heterogeneity observed. The clinical im-
plications of this heterogeneity are multiple; first, sam-
pling or imaging part of the tumor to assess the biology
driving its growth is not necessarily representative of the
tumor bulk (intratumor heterogeneity) or tumors in
other patients (intertumor heterogeneity). Treatment
decisions based on this can thus be inadequate. Second,
different populations within or between tumors can differ
in sensitivity to the drug already at the start of treatment,
or display different rates at which resistance develops.
As a consequence, tissue banks that hold large sample
numbers to cover the breadth of this diversity are re-
quired to measure relevant parameters, and models to
manipulate and perform functional experiments should
be generated to reflect the heterogeneity observed in the
patients. These considerations explain why genetically
engineered mouse models (GEMMs) are inadequate to
mimick broad, unselected patient populations; they are
driven by a very well defined set of driver mutations
which can never reflect the diverse spectrum of genetic
aberrations found in human tumors. Another important
concern is that the time within which these tumors arise
in mice does not allow for the ‘evolution’ observed in
patient derived tumors. In addition, for some diseases
like esophagogastric cancer, appropriate GEMMs are not
available making the rationale to invest in a viable tissue
biobank, including patient derived xenograft (PDX)
models and primary cell lines to study tumor biology,
even more apparent.
One of the key pathways for normal gastrointestinal
development, the Hedgehog signaling pathway, is also
involved in the formation and progression of malignan-
cies of the upper GI tract [2]. As a consequence, it is
being considered as a therapeutic target in a broad range
of tumors [3,4]. The pathway is activated by binding of
Hedgehog ligands (SHH, IHH, or DHH) to their recep-
tor Patched (PTCH), which then alleviates the inhibitory
function of PTCH on the activating receptor Smooth-
ened (SMO). This in turn leads to activation of down-
stream mediators, such as the Gli transcription factors,that orchestrate the transcriptional response and func-
tional outcome of pathway activation.
As cells of the pancreas move through the different
stages of malignant progression towards PDAC, they ex-
press increasing amounts of SHH [5]. This ligand is not-
ably absent from both the developing as well as the
healthy adult pancreas, but its aberrant expression in the
pancreas has been shown to drive tumor progression,
and inhibition of its downstream signaling pathway is ef-
fective in some preclinical models for PDAC [6,7]. For
EAC similar data have been reported [8,9], but know-
ledge on the role of Hedgehog proteins in cancers of this
organ is much more limited compared to PDAC. Inter-
estingly, Hedgehog ligands have been described to be
expressed in healthy esophagus and are required for the
homeostasis of this organ [10]. This implies that the
expression of Hedgehog ligands in cancer tissue is not
exclusive to epithelial cells that have never expressed
these ligands, but also that the response to these ligands
in a tumor setting is not exclusive to cells that are
Hedgehog-naive.
We describe in this paper the establishment of a panel
of 29 relevant PDXs from esophagogastric and pancreatic
cancers, and show that these PDXs reflect the histological
and biochemical characteristics of the original cancer.
Matching primary cell lines from the PDX models can be
genetically manipulated and used to further study tumor
biology and signaling capacity. These models should prove
valuable for profiling approaches and detailed functional
studies requiring living tissue. In addition, we demonstrate
an active (paracrine) Hedgehog signaling mode by both
tumor types, the magnitude of which has not been com-
pared directly in previous studies.
Methods
Ethics statements
Both the collection and storage of patient material were
approved by the institute’s medical ethical committees,
and performed according to the guidelines of the Helsinki
Convention. Informed written consent was obtained from
all patients. Animal work was performed according to pro-
tocols approved by the animal experiment ethical commit-
tee (DTB102348, LEX102774). All surgical procedures
were performed under isoflurane anesthesia.
Pathology
The surgical resection specimen was inspected and proc-
essed according to national and international guidelines
[11]. The microscopic assessment was performed by an
experienced GI-pathologist and the final diagnosis was set
in accordance with the WHO classification [12]. Adeno-
carcinomas and squamous cell carcinomas were classified
according to site of origin and tumor stage, in accordance
with the pTNM classification of malignant tumors [13].
Damhofer et al. Journal of Translational Medicine  (2015) 13:115 Page 3 of 14Immunohistochemistry
Patient tumor material or xenografts were fixed in 4%
formalin prior to paraffin embedding. Sections of 5 μm
were prepared on a microtome. Tissue sections were
deparaffinized and heat mediated antigen retrieval was
performed using Tris-EDTA buffer solution pH 9 for
Hedgehog staining or 10 mM sodium citrate solution
pH 6 for other stainings. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide in PBS. Aspecific
staining was blocked using Ultra-V Block (Immunologic)
for 10 min at room temperature. Primary antibodies
were diluted in normal antibody diluent (KliniPath), ap-
plied on tissue sections and incubated overnight at 4°C
in a humidified chamber. For amplification of signal
Brightvision + post antibody block (Immunologic) was
used prior to the addition of the secondary antibody;
poly-HRP-anti Ms/Rt/Rb IgG (Immunologic) both
for 30 min at room temperature. Visualization was
performed using Vector® NovaRED™ (Vector Labs) ac-
cording to manufacturer’s protocol, counterstained with
30% haematoxylin and tissue sections were mounted
with non-aqueous medium. Antibodies used for immu-
nohistochemistry were: anti-alpha smooth muscle actin
(Abcam, 1:1000); anti-Hedgehog (clone H160, Santa
Cruz, 1:1500), anti-Cytokeratin 19 (clone RCK108, Bio-
Genex, 1:1000), anti-pan cytokeratin (clone AE1/AE3,
Dako, 1:100).
Tumor and cell line xenografting
Freshly excised tumor pieces (approx. 3×3×3 mm) ori-
ginating from primary tumor or liver metastasis were
washed several times in PBS containing 10 μg/ml genta-
mycin (Lonza) and 1% Penicillin-Streptamycin. Pieces
were grafted subcutaneously into the flank of immuno-
compromised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (JAX 005557) with Matrigel (BD). Animals were
bred and maintained at the local animal facility accord-
ing to the legislation and ethical approval was obtained
for the establishment of patient derived xenografts
(PDX). Monitoring for tumor take was done up to
9 months after transplantation. If no tumor was palpable
on animals after this period, grafting was considered to
be not successful. After outgrowth of patient tumor and
reaching a size of approximately 500 mm3, PDX tumors
were harvested and passaged, and/or used to establish
in vitro cultures. Tumors were typically retransplanted
three times (i.e. up to p4). To establish xenograft tumors
from isolated EAC007B cell line, 106 cells were injected
into the flank of NSG mice in PBS with 50% Matrigel.
For orthotopic injection of PC053M cells into the
pancreas, mice received pre-operative analgesics by sub-
cutaneous administration of meloxicam (1 mg/kg) and
were operated under isoflurane anesthesia (0.5-2.5% in
100% oxygen). Briefly, a small incision was made in theabdominal skin and peritoneal wall. Thereafter, pancreas
was gently pulled out and 106 PC053M cells in 50 μl
PBS + 5% Matrigel were injected using a 1 ml syringe
and 25G needle. After placing back the pancreas into
the abdominal cavity, both muscle and skin layers were
closed by surgical suture.
Isolation and propagation of primary cultures
Harvested xenografts were minced, placed in 8% FBS
containing IMDM with collagenase IV (0.5 mg/ml,
Sigma) in a tube and incubated at 37°C for 60 min with
vortexing every 10 min. The dissociated suspension was
passed through a 70 μm strainer to obtain single cells
and washed with culture medium. Cell aggregates
retained on top of the filter were put in a separate dish.
Isolated cells and aggregates were grown in IMDM con-
taining 8% FBS. Purity of the epithelial culture was
assessed by flow cytometry with FITC labelled human
specific EpCAM antibody staining (DAKO, F0860 at
1:100). For selective trypsinization, cultures were washed
twice with PBS, followed by 2–3 min incubation with
0.05% Trypsin/0.02% EDTA solution at 37°C. Detached
cells were gently washed away with 8% serum containing
medium and selective removal of fibroblast was repeated
once cells reached confluence.
Flow cytometry
Cell were harvested with trypsin-EDTA solution (Lonza)
and washed in FACS buffer (PBS with 1% FBS). Staining
was performed with hybridoma supernatant containing
either anti-SHH antibody clone 5E1 (0.08 μg/ml) or
anti-Myc antibody clone 9E10 (1 μg/ml), diluted 1:5 in
FACS buffer for 30 min at 4°C. Secondary APC labeled
anti-mouse antibody (BD, 550826) was used at a 1:500
dilution. After washing, cells were resuspended in FACS
buffer containing 1 μg/ml propidium Iodide (PI, Sigma)
and acquired on a FACSCanto II (BD, Franklin Lakes,
NJ). In case of the EAC007B line, cells were costained
with FITC labelled anti-human EpCAM antibody to
allow for exclusion of mouse fibroblasts from the ana-
lysis (DAKO, F0860 at 1:100). Data were analyzed with
FlowJo 7 (Tree Star, Ashland, OR).
Hedgehog reporter assay
Mouse embryonic fibroblasts stably transduced with the
GBS-GFP reporter construct (GGM cells, [21]) were
grown under standard cell culture conditions in high
glucose DMEM (Lonza) containing 8% FBS (Lonza) and
0.5% Penicillin/Streptamycin (Lonza). For signaling assay
GGM cells were seeded in 96 well plates (Greiner) and
grown to confluence. 10.000 primary cancer cells or
2.000 knockdown PC053M cells were seeded per well on
top of the GGMs in serum free medium (DMEM,
Lonza) with or without the addition of 100 nM KAAD-
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ture, images were taken on a Zeiss fluorescence micro-
scope and percentage of GFP positive cells was
determined by flow cytometry on a FACSCanto II.
RNA isolation and quantitative real-time PCR
Primary cells grown in culture were lysed in TriPure
reagent (Roche) and RNA was isolated according to
the manufacturer’s protocol. cDNA was synthesized
using Superscript III (Invitrogen) and random primers
(Invitrogen). Real-time quantitative RT-PCR was per-
formed with SYBR green (Roche, Basel, Switzerland)
on a Lightcycler LC480 II (Roche). Relative expression
of genes was calculated using the comparative thresh-
old cycle (Cp) method and values were normalized to
reference gene GAPDH. Primer sequences used for
quantitative RT-PCR amplification were as follows for
GAPDH (fw 5′-GAAGGTGAAGGTCGGAGTC-3′, rv
5′- AAGGTGAAGGTCGGAGTCAAC-3′), SHH (fw
5′-CGGCTTCGACTGGGTGTACT-3′, rv 5′-GCAG
CCTCCCGATTTGG-3′), IHH (fw 5′-CACCCCCAAT-
TACAATCCAG-3′, rv 5′-CGGTCTGATGTGGTGAT
GTC-3′), and DHH (fw 5′-TGATGACCGAGCGTTG-
TAAG-3′, rv 5′-GCCAGCAACCCATACTTGTT-3′).
SHH knockdown
Lentivirus was produced by transfecting HEK293T cells
with the pLKO transfer construct targeting SHH (Sigma
Mission library TRC clone number 0000033304) or a
scrambled non-targeting control shRNA (shc002) to-
gether with the packaging plasmids pMD2.G and
psPAX2 using Fugene HD (Roche). 48 h and 72 h after
transfection supernatant was harvested and filtered
through a 0.45 μm filter (Millipore, Germany). 60% con-
fluent PC053M cells were transduced with the harvested
virus in the presence of 5 μg/ml polybrene (Sigma) over-
night. Two days after transduction cells were selected
for stable transduction with 1 μg/ml puromycin (Sigma).
Statistics
All statistical test were performed using GraphPad Prism
5 sofware, and Student’s t-test (two-sided) was used to
compare grafting time between PDAC and EC patient-
derived xenografts as well as the inductions measured in
the Hh reporter assay.
Results
Tumor tissue bank establishment
To establish the appropriate tools to study pancreatic and
esophagogastric malignancies, we set up a tissue collection
program (biobank) in our institute. Patients with a suspi-
cion of pancreatic or esophagogastric cancer, scheduled for
operation, endoscopic procedures, or tumor biopsies from
a supposedly metastatic site were asked for participation inthe respective biobank. Written informed consent was ob-
tained from all participating patients. Tissue from pancre-
atic cancer patients was in most cases received from
resected specimen after gross examination by an experi-
enced pathologist to confirm location and origin of the
tumor. If patients were found to be inoperable due to lo-
cally advanced or metastatic disease, tissue was collected
perioperatively through additional biopsies after the pres-
ence of malignancy (e.g. liver, peritoneum, distant lymph
nodes) was confirmed by a pathologist.
Tissue biopsies from patients with suspicion for esopha-
geal squamous- or adenocarcinoma were collected during
diagnostic endoscopy procedure, surgery or sampling of
metastatic lesions. Specimens obtained after surgical re-
section were processed similarly to pancreatic tissue after
gross pathological examination. For biobanking purposes
collected tissue material was immediately frozen in liquid
nitrogen or prepared for xenotransplantation in immuno-
compromised mice.
In total, 63 pancreatic ductal adenocarcinoma (PDAC),
47 esophageal adenocarcinoma (EAC), and 12 esopha-
geal squamous cell carcinoma (ESC) patients donated
samples for the respective biobanks, which were started
in 2011 and 2013 respectively. In the PDAC cohort from
the 65 samples collected, 77% were derived from the pri-
mary tumor and 23% from metastatic sites. From two
patients we were able to collect tissue from primary
tumor as well as distant metastasis. The majority of the
metastatic material originated from liver (13 out of 14
samples); one lymph node metastasis was collected as
well. The esophagus carcinoma (EC) biobank comprises
64 tissue samples from 59 different patients, with 55% of
the samples being biopsies taken from the primary
tumor before neo-adjuvant chemoradiation therapy, 20%
were collected from resected tumor specimen, and 25%
of the tissue originated from various (strongly diverse)
metastatic sites. The clinical characteristics of these two
cohorts are shown in Table 1.
Generation of xenografts from pancreatic and esophageal
carcinomas
To establish patient derived xenografts from the in-
cluded patients, fresh tissue pieces were immersed in
Matrigel and subcutaneously implanted into the flank of
immunocompromised (NSG) mice. To date 108 pieces
of tissue from a total of 101 upper GI tract cancer pa-
tients have been implanted (47 PDAC, 49 EAC, and 12
ESC). From the 47 PDAC tumor pieces implanted, 12
PDAC models could be established from 11 different pa-
tients, with one patient having the primary tumor as well
as the liver metastasis growing in mice. Four transplant-
able grafts were established for ESC, and 13 for EAC.
These include two matched sets of PDXs from the same
patient of which in one case biopsy material from the
Table 1 Clinical characteristics of Biobank patients
PDAC n = 63 EC n = 59
Gender n (%) Gender n (%)
Male 32 (51) Male 49 (83)
Female 31 (49) Female 10 (17)
Age mean (±SD) 68 (9) Age mean (±SD) 64 (11)
Stage n (%) Stage n (%)
I 4 (6) I 4 (6)
II 31 (49) II 5 (8)
III 10 (16) III 46 (62)
IV 18 (29) IV 9 (14)
Diagnosis n (%) Diagnosis n (%)
PDAC 63 (100) EAC 47 (80)
ESC 12 (20)
Tissue location n (%) n = 65 (63 patients) Tissue location n (%) n = 64 (59 patients)
Primary tumor 50 (77) Biopsy tumor 35 (55)
Metastasis 15 (23) Resected tumor 13 (20)
Metastasis 16 (25)
Grafting outcome n (%) 47/65 grafted Grafting outcome n (%) 61/64 grafted
Successful 12 (26) Successful 17 (28)
Unsuccessful 26 (55) Unsuccessful 32 (52)
Ongoing 9 (19) Ongoing 12 (20)
Success rate 12/38 (32%) Success rate 17/49 (35%)
(excl. ongoing grafts) EAC 13/39 (33%)
ESC 4/10 (25%)
(excl. ongoing grafts)
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in the other case both the pre-chemoradiation treatment
biopsy as well as the post-treatment resection material
growing successfully in animals. Take rates (i.e. the
ability of a donor tumor to successfully be propagated in
mice) were similar between the different malignancies,
32% for PDAC, 33% for EAC, and 25% for ESC (Table 1).
Ongoing grafting attempts were excluded from the take
rate statistics, as no clear conclusion could be drawn for
these materials yet.
Grafted tumors differed quite extensively in the time
required to grow to a transplantable size, ranging be-
tween 3 and 37 weeks. Esophageal carcinomas required
on average 13.6 weeks (±5.8 s.d.), whereas PDAC tumors
had grown to sufficient size to allow for transplantation
after 20.7 weeks (±9.8 s.d.), making the esophageal tu-
mors the slightly faster growing PDX models (p = 0.022).
There was no significant difference in growth rate be-
tween the EAC and ESC xenograft tumors (p = 0.24).
Clinical and pathological characteristics of all the 29
PDX models are summarized in Table 2.
As can be observed from the histology of 8 representa-
tive patient tumors and their derived xenografts, overalltumor morphology was well preserved in the PDXs
showing strong resemblance to the respective human
counterpart (Figure 1). Differentiation grades scored by
a pathologist showed that tumor grade of the PDX
model tended to reflect the original patient tumor
(Table 2). Immunohistochemical staining specific for hu-
man cytokeratin 19 (CK19) on the PDX tissue confirmed
a human origin of the epithelial cell compartment, with
better staining in the moderately- to well-differentiated
models compared to the poorly differentiated esophageal
tumors EAC023 and EAC027 (Figure 1C,F). Similar
results were obtained by using a pan-cytokeratin anti-
body on esophageal PDXs (Figure 1G), reflecting a down-
regulation of overall cytokeratin expression in poorly
differentiated esophageal tumors compared to their more
differentiated counterparts. Closer characterization of the
stroma of a p1 PDX tumor revealed that the vast majority
of the stroma was of mouse origin, indicating replacement
of human stromal cells by that of the host early on in the
establishment of these tumors (Additional file 1). Thus,
we have been able to set up a panel of histological mimics
of human upper GI tract tumors, which span the range of
heterogeneity in morphology observed in patients.
Table 2 Clinical and pathological characteristics of established xenograft models
ID Gender Age Location Stage (TNM) Diagnosis Diff. patient Diff. xeno Xeno take* Cell lines Treatment+
PC028 F 74 liver metastasis pTxNxM1 PDAC moderate moderate 4 yes none
PC053M M 78 liver metastasis pTxN1M1 PDAC moderate poor 12 yes none
PC053B M 78 biopsy tumor pTxN1M1 PDAC na poor 12 yes none
PC067 F 73 resected tumor pT3N1M0 PDAC poor moderate 26 yes none
PC072 M 65 resected tumor pT3N1M0 PDAC moderate moderate 24 no growth none
PC076 M 64 resected tumor pT3N1M0 PDAC poor-moderate moderate 33 yes none
PC084 M 83 liver metastasis pTxN1M1 PDAC moderate-well moderate 11 yes none
PC086 M 66 resected tumor pT4N1M0 PDAC moderate moderate 18 na none
PC090 F 78 resected tumor pT4N1M0 PDAC moderate well 19 yes none
PC093 M 61 resected tumor pT4N1M0 PDAC moderate moderate 37 ongoing none
PC096 F 62 liver metastasis pTxNxM1 PDAC moderate moderate 29 ongoing none
PC099 F 46 liver metastasis cT3NxM1 PDAC well moderate 23 ongoing none
EAC007B F 50 biopsy tumor pT3N1M0 EAC moderate moderate-well 10 yes none
EAC007R F 51 resected tumor pT3N1M0 EAC moderate poor-moderate 19 yes chemoradiation
ESC008 F 37 resected tumor pT4N0M0 ESC moderate poor-moderate 3 na chemoradiation
EAC018 M 73 resected tumor pT3N1M0 EAC moderate moderate-well 16 yes chemoradiation
EAC023 M 58 biopsy tumor pT3N2M0 EAC poor poor 14 yes none
EAC026 M 69 lymph node
metastasis
pT2N2M0 EAC poor poor 16 yes chemoradiation
EAC027 M 66 adrenal gland
metastasis
pT3NxM1 EAC poor poor 14 yes radiation
EAC031B M 78 biopsy tumor pT3N3Mx EAC moderate poor 14 yes none
EAC031M M 78 liver metastasis pT3N3Mx EAC moderate moderate 17 yes chemotherapy
EAC033 M 54 liver metastasis pT4N2M1 EAC poor poor 16 yes chemotherapy
EAC037 M 68 thoracle TH
metastasis
na EAC poor poor 11 yes chemotherapy
EAC038 M 76 lung metastasis pT3N1M0 EAC poor poor 28 na chemoradiation
ESC040 F 67 pelvis metastasis pTxN2Mx ESC moderate poor-moderate 17 ongoing chemoradiation
EAC041 M 73 biopsy tumor pTxN1M0 EAC moderate moderate 3 ongoing none
ESC043 M 58 biopsy tumor pT3N1Mx ESC na moderate-well 10 na none
ESC049 F 66 biopsy tumor pT3N1M0 ESC moderate moderate 12 na none
EAC050 M 69 biopsy tumor pT3N2Mx EAC na poor-moderate 11 na none
*time in weeks required for the primary patient material to grow out and be retransplanted.
+neo-adjuvant treatment before resection.
Abbrevations: M male, F female, Diff. Differentiation grade, na not assessed due to limited or inconclusive material, PDAC pancreatic ductal adenocarcinoma, EAC
esophageal adenocarcinoma, ESC esophageal squamous cell carcinoma.
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tumors
Tumors grafted in mice allow for a strong enrichment of
epithelial cells, and given the low tumor cell content often
found in these tumors (most notably in PDAC), this has
been instrumental in establishing cell lines. Second or
higher passage PDXs at a size of around 500 mm3 were
excised, enzymatically and mechanically dissociated, and
primary lines were established. Suspensions were placed
under adherent conditions and monitored for epithelial
cell content by flow cytometry. Mouse cells were depletedby selective trypsin/EDTA treatment during the first pas-
sages (see Methods section).
In case of the EAC007B cell line, it was not possible to
remove the fibroblasts from the cultures, and even after
more than 15 passages these cells were found to be re-
quired to support attachment and growth of the human
epithelial cell clusters. Whereas most cultures (among
which the PDAC cultures PC053M and PC067 shown in
Figure 2A) were found to display the cobblestone morph-
ology characteristic for epithelial cells, the esophageal line
EAC027 grew semi-adherently with viable floating cell
Figure 1 (See legend on next page.)
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Figure 1 Morphology of selected primary patient tumors and the corresponding patient-derived xenograft. A) H&E-stained sections of original
patient material and B) first passage xenograft tumors (p1, lower row) demonstrate overall conserved histological features. C) CK-19 staining using
human antigen specific antibody on xenograft tumors. D-E) As for panels A-B, for EAC tumors and xenografts. F) CK-19 staining on EAC PDX
tissue. G) Pan-cytokeratin staining on EAC PDXs. Scale bar; 200 μm.
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established EAC lines [14]. Two of the primary lines
(EAC007B and PC053M) were kept in culture for more
than 12 months to test for their in vitro longevity. Both
lines have been grown for more than 20 passages without
any sign of growth decline, and rather tended to accelerate
in growth after reaching approximately passage 10–15.
The morphology of these cell lines was consistent in time
(not shown). The histology of tumors that grew from these
cells injected in mice (subcutaneously for EAC007B and
orthotopically for PC053M) strongly resembled that of
regrafted PDX tumors (Figure 2B-C).
Hedgehog ligand expression in upper GI tract tumors
Hedgehog ligands and activation of its downstream
pathway have been implicated in the genesis and pro-
gression of several diseases of the gastrointestinal tract
[2]. To formally assess the expression of these ligands in
our primary cultures, transcript levels were measured by
qRT-PCR and robust expression was found for the Sonic
(SHH) and Indian Hedgehog (IHH) paralogs (Figure 2D).
Protein levels on the surface of these cells were
confirmed by flow cytometry using the 5E1 antibody
(Figure 2E). The limited expression found for Desert
Hedgehog (DHH) fits with its very restricted expression
pattern in healthy organisms [15], and the expression of
the IHH homolog in EAC cells is in line with profiling of
ligands in patient tissue [16]. Expression of both IHH
and SHH paralogs has been reported in PDAC biopsies
and cell lines [2], but most studies have typically focused
on the better characterized SHH protein. The presence
of one or more Hedgehog ligand implies that there is se-
lective pressure on tumor cells to express Hedgehog, but
that the exact protein expressed is not critical and that
either IHH, SHH, or both will suffice. It also suggests
that in the divergent evolution of the two paralogs some
of their regulatory mechanisms are coevolved, and that
these mechanisms exist throughout the organs of the
upper GI tract.
In agreement with the expression data from the primary
cell lines, immunohistochemistry for Hedgehog ligands
(presumably SHH) confirmed a widespread expression in
the epithelial compartment of the human tumors and this
was conserved in the PDXs (Figure 3). Generally stronger
staining was observed in PDAC (Figure 3A) than EAC
tissue (Figure 3B).
Stromal activation marked by alpha smooth muscle
actin (α-SMA) was apparent in all tumors tested, but wedid observe that the non-epithelial areas were larger in
the patient tumors than they were in the PDXs, specific-
ally for PDAC. This possibly contributed to the higher
staining intensity for α-SMA observed in the PDXs de-
rived from these patients, as a consequence of a higher
tumor/stroma cell ratio in these tumors. Differences
were also observed between EAC and PDAC PDXs, the
latter showing typically larger areas of α-SMA positivity.
This reflected the known high stromal content of PDAC
tumors in general [17], and as found in our patient tu-
mors. These differences in stromal activation, as well as
SHH staining intensity, were consistently found over
several consecutive passages (Additional file 2).
Paracrine Hedgehog signaling in cell lines
As mentioned above, pancreatic tumor cells express in-
creasing amounts of SHH as they progress towards fully
established PDAC, however, they are unresponsive to
the ligand themselves. Instead, the ligand signals to re-
sponsive cells in the adjacent stroma, activating the
pathway in the non-malignant compartment [18,19]. A
similar signaling model has been shown in Barret’s
esophagus, a pre-malignant condition that may progress
towards adenocarcinoma, but there are no conclusive
studies addressing the mode of Hedgehog signaling in
EAC yet [16]. Hh pathway inhibitors are already success-
fully used to treat patients with basal cell carcinomas
(BCC), and are currently being tested in clinical trials
for the use in several other malignancies [20]. Although
these efforts indicate a certain level of (perceived) im-
portance of this pathway in human cancer, unfortunately
preliminary reports have been disappointing. Especially
in patients with advanced pancreatic cancer, which is
probably due to our lack of understanding the stromal
response.
We have recently developed a fibroblast reporter cell
line in order to quantitatively assess the paracrine signal-
ing potency and range of cancer cell-derived Hedgehog
ligands. These cells (GBS-GFP MEFs; denoted GGM) ex-
press eGFP under the control of eight concatemerized
Gli-binding site motifs, which are recognized by the GLI
transcription factors mediating the downstream tran-
scriptional response following canonical Hedgehog path-
way activation. These reporter cells respond to known
Hh pathway stimulating agents as well as overexpressed
and tumor cell-derived Hedgehog proteins. This activa-
tion can be blocked by administering either Hh blocking
antibodies or small molecule inhibitors [21].
Figure 2 Morphology of primary cell lines and Hedgehog ligand expression A) Phase contrast images of cell lines generated from xenografts.
B) H&E stained tumor grown from orthotopically injected PC053M PDAC cells (right panel) compared to p1 PDX tumor (left panel). C) As for
panel using subcutaneous injections of EAC007B, compared to p2 PDX. D) Hh ligand expression determined by qPCR of respective cell lines.
E) Surface expression of Hh protein on primary lines measured by flow cytometry using 5E1.
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Figure 3 Hedgehog ligand expression and stromal activation in xenograft tumors A) Immunohistochemical staining shows expression of
Hedgehog ligand in the PDAC patient material as well as in matching xenografts. Surrounding tissue is positive for stromal activation marker alpha
smooth muscle actin (α-SMA). B) As for panel A, on the esophageal cancer primary tumors and xenografts. Shown are first passage grafts (p1).
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of GGMs and cocultured for a period of three days in the
absence of serum to allow for full pathway activation and
accumulation of eGFP in the reporter cells (Figure 4A).
Strong activation of eGFP expression could be observed in
reporter cells in close proximity to the tumor cells, but
not in those cells at larger distances from the ligand
source, a function of the hydrophobic properties of
Hedgehog protein, which is apparently consistent be-
tween different tumor types. Reporter activation could
be ablated by treating cocultures with the Smoothened
antagonist KAAD-cyclopamine. Flow cytometry was
used to quantify the percentage of GFP-positive cells in
the cocultures. All tested primary cell lines were able to
activate GFP expression in the reporter cells to differentmagnitudes, and this activation was sensitive to cyclo-
pamine (Figure 4B). Generally, PDAC cells were more
potent in activating Hh response than the EAC lines,
which matches the expression levels of the HH paralogs
determined in Figure 2.
For a more targeted approach and to test if our pri-
mary cell lines are amenable to genetic manipulation, we
decided to perform stable knockdown of SHH in the
PDAC line PC053M, as these cells do not express the
other HH paralogs that could confound interpretation of
the results. PC053M cells were lentivirally transduced
with a control or SHH targeting shRNA, and after selec-
tion with puromycin, target gene transcript levels were
measured by qPCR (Figure 4C). Successful reduction of
protein levels was assessed by Hh surface staining using
Figure 4 Hh expression is maintained in primary cell lines and can activate reporter cells in a gradient A) The fibroblast Hh pathway reporter cell
line GGM was cocultured with indicated primary cell lines for 3 days. Representative fluorescence and brightfield images show GFP expression in
reporter cells adjacent to cancer cells. Administration of Hh inhibitor KAAD-cyclopamine (100 nM) strongly reduced pathway activation. B) Quantification
of GFP positive GGMs following coculture by flow cytometry. ns, not significant; *** p < 0.001. Percentage of GFP positive GGMs in the absence of tumor
cells was 0.135 ± 0.05%, and 0.141 ± 0.06% in the presence of KAAD-cyclopamine. C) qPCR of SHH transcript in shCTR and shSHH PC053M cells relative to
GAPDH. D) PC053M knockdown cells stained with anti-HH antibody 5E1(red) or isotype control (grey). Representative histogram overlay of flow cytometry
experiment is shown. E) GGM coculture with knockdown cells imaged after 3 days. F) Quantification of GFP positive GGMs after coculture by flow
cytometry shows strong reduction of paracrine pathway activation after knockdown of SHH in PC053M cells. *** p < 0.001.
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GGMs showed a strongly diminished capacity of SHH
knockdown cells to active Hh response (Figure 4E,F).
These results demonstrate that the primary cells are
amenable to genetic manipulation and provide a power-
ful tool to study disease biology.
Discussion
Despite encouraging progress in the treatment and
prognosis of most tumor types, esophagogastric andpancreatic cancer are almost as lethal as they were de-
cades ago [22]. There is a clear drive to find new drugs
to combat these tumors, but the numerous candidate
agents that showed promising therapeutic efficacies in
preclinical studies have failed to improve outcome in
clinical trials [20]. A number of factors can be held ac-
countable for these failed trials, including the obvious
problem that several preclinical models have not man-
aged to recapitulate the heterogeneity observed in the
relevant patient population [23,24]. In addition, they
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ance mechanisms that are a result of tumor evolution over
the course of many years of disease progression in the
patient.
To match the relevant tumor biology, we have gen-
erated a panel of PDXs that mirror the (immuno)
histochemical and biochemical features of human dis-
ease. For three patients, this panel contains matched
xenografts from the primary tumor and metastasis or
post-chemoradiation material. These will provide ex-
cellent tools to study tumor development and evolu-
tion over time, as well as to investigate changes in
the primary tumor in response to therapy. Further-
more, we created matching cell lines amenable to
genetic manipulation like lentiviral transductions and
the knockdown of genes. Upon injection, these cells
formed tumors histologically similar to those grown
from grafted tumor pieces. Having such cultures
available greatly broadens the possibilities for studies
that genetically address the functional relevance of
potential targets in tumors that closely resemble the
patient tumor. In this study we demonstrate the si-
lencing of one morphogen as an example, however,
the availability of a genome-wide shRNA library en-
ables us to target any gene, pending viability of cells
knocked down for it.
PDX models are not without limitations. For instance,
we have observed that quite long periods of time are
required for grafted tumors to grow, especially for
PDACs. This limits the use of these models as avatars
to guide (neo)adjuvant treatment or first line treatment
for metastatic disease. We were able to generate cell
lines from 60% of xenografts, but have not been able to
correlate this to clinical parameters like tumor stage,
grade or patient survival. PDXs that were passaged sub-
cutaneously did not yield the metastases that are char-
acteristics of the diseases they are derived from, and for
this orthotopic transplantation is necessary [24,25].
Despite these caveats, having an extensive range of
PDXs to perform experimental work on is preferable
over having to rely on a limited number of genetically
defined mouse models for preclinical experiments.
Our biochemical data reveal a remarkable congruence
in the expression of Hedgehog ligands between the dif-
ferent tumors, PDXs and cell lines. Berman et al. had
previously demonstrated that Hedgehog ligands were
expressed in tumors throughout the entire gastrointes-
tinal tract, and that this was functional [2]. Although
later studies did show that some of the conclusions in
the paper were possibly overstated, our results do indicate
that the expression and distribution of Hedgehog ligands
are conserved in the upper GI tract tumors tested.
Despite the shared expression of Hedgehog ligands
between EAC and PDAC, some differences in the levelsdo exist and these could be caused by the dissimilarities
between Hedgehog signaling in the healthy pancreas and
esophagus. In the pancreas, SHH is absent during devel-
opment as well as adult life, but expression is activated
after malignant transformation through mechanisms that
are not entirely understood. In the esophagus, SHH
expression during development is needed for proper
foregut separation and the formation of squamous epi-
thelium [26]. Moreover, in adult tissue Hedgehog ligand
expression stimulates proliferation of epithelial precur-
sor cells [10]. The exact role of Hedgehog ligands during
malignant progression in this organ, or how expression
is regulated here, remains to be determined. The latter is
further complicated by the apparent contradictory sig-
naling mode for Hedgehog in adenocarcinomas versus
squamous cell carcinomas. Hedgehog expressing adeno-
carcinomas were described to signal to the adjacent
stroma [16] as well as in an autocrine fashion [9], how-
ever, also ligand independent pathway activity was ob-
served [27,28]. Squamous cell carcinomas on the other
hand appear to arise and be maintained by autocrine
pathway activation in the epithelium [8,10]. Our primary
cell line models at the moment are restricted to the
adenocarcinoma type, but it will be interesting to in-
clude and test squamous carcinoma cells for their para-
crine signaling activity.
In light of the paracrine signaling by Hedgehog
ligands, the sustained expression of these proteins in
culture is remarkable. For PDAC it is well know that the
responsiveness resides in cells from the stroma, which
are of course absent from the epithelial monocultures.
In addition, the expression of these proteins are not
known to rely on gene duplications, promoter mutations
or other genomic alterations and therefore, a plastic
regulation at the level of epigenetics or more upstream
could be driving this expression. The retained produc-
tion of this ligand in culture does suggest it to be some-
how hard-wired in these cells.
Conclusions
Therapeutic strategies aiming at targeting and ablating
the reactive tumor stroma show promising results in a
group of pancreatic cancer patients [29], however the
molecular mechanisms and exact tumor-promoting
and -inhibiting functions of the stroma are still not very
well understood. The established PDXs that retain a react-
ive stromal microenvironment, and the availability of
matching primary cell lines, will enable future studies to
address their responses to different treatment modalities.
This will not only aid in the development of new treat-
ment strategies, but hopefully also in gaining mechanistic
insight in how some tumors respond to certain regimens
and others do not. This, in turn, can shed light on the
biology underlying these malignancies.
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Additional file 1: Human stroma is replaced by cells of murine
origin early in PDX outgrowth. Flow cytometric analysis of patient-
derived xenograft PC084 passage 1. Tissue was enzymatically dissociated and
single cell suspension was stained with FITC labelled anti-human EpCAM
antibody or biotin labelled anti-mouse H2Db antibody (BD Bioscience, 1:100)
followed by incubation with streptavidin-APC (Invitrogen, 1:500). Single and
double stainings reveal around 70% human epithelial cells and 30% cells of
murine origin. Stainings indicated in panels.
Additional file 2: Hedgehog ligand expression and stromal activation
in xenograft tumors over several passages. A) Immunohistochemistry for
Hedgehog ligand (SHH), and the stromal activation marker alpha smooth
muscle actin (α-SMA) in the PDAC xenografts over passages p2-4.
B) As for panel A, on the EAC xenograft passages p2-4. Earlier passage
and original patient tumor are shown in Figure 3. na, not assessed.
Abbrevations
HH: Hedgehog; PDAC: Pancreatic ductal adenocarcinoma; ESC: Esophageal
squamous cell carcinoma; EAC: Esophageal adenocarcinoma; EC: Esophageal
cancer; GGM: Gli-binding site-GFP-mouse embryonic fibroblasts;
GI: Gastrointestinal; PDX: Patient derived xenograft; GAPDH: Glyceraldehyde
3-phophate dehydrogenase.
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